ArticleCell reports. Medicine2023

Preclinical development of a chimeric antigen receptor T cell therapy targeting FGFR4 in rhabdomyosarcoma.

Meijie Tian et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.